Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Rev Esp Quimioter ; 35 Suppl 1: 6-14, 2022 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-35488817

RESUMO

Severe lower respiratory tract infection is a common issue in Intensive Care Units that causes significant morbidity and mortality. The traditional diagnostic-therapeutic approach has been grounded on taking respiratory samples and/or blood cultures as soon as possible and starting empirical antibiotic therapy addressed to cover most likely pathogens based on the presence of the patient's risk factors for certain microorganisms, while waiting for the culture results in the following 48-72 hours to adequate the antibiotic treatment to the sensitivity profile of the isolated pathogen. Unfortunately, this strategy leads to use broad-spectrum antibiotics more times than necessary and does not prevent possible therapeutic failures. The recent development of rapid molecular diagnostic techniques, based on real time polymerase chain reaction (RT-PCR), makes it possible to determine the causative agent and its main resistance pattern between 1 and 5 hours after sampling (depending on each tecnique), with high precision, some of them reaching a negative predictive value greater than 98%, facilitating the very early withdrawal of unnecessary broad-spectrum antibiotics. Its high sensitivity can also detect unsuspected pathogens based on risk factors, allowing adequate treatment in the first hours of stay. This short review discusses the potential usefulness of these techniques in critically ill patients with lower respiratory tract infection and advocates their immediate implementation in clinical practice.


Assuntos
Estado Terminal , Pneumonia , Antibacterianos/uso terapêutico , Humanos , Unidades de Terapia Intensiva , Pneumonia/tratamento farmacológico
2.
Rev Esp Quimioter ; 34 Suppl 1: 52-56, 2021 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-34598428

RESUMO

It has been almost two years since COVID-19, a disease caused by a new coronavirus called SARS-CoV-2, was declared a pandemic by the World Health Organization. The entire scientific and medical community was put to the test during the following months to find the best therapeutic strategy to save lives. Although some antivirals and anti-inflammatory drugs are being tested in different clinical trials with some controversial results, this short review will focus on corticosteroids usefulness and ventilatory support principles, as they have become two essential therapeutic pillars for those patients who need hospital admission due to respiratory failure.


Assuntos
COVID-19 , SARS-CoV-2 , Corticosteroides/uso terapêutico , Antivirais/uso terapêutico , Humanos , Pandemias
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...